Last updated: April 7, 2026
Case Overview
AbbVie Inc. filed a patent infringement lawsuit against Princeton Pharmaceutical Inc. in the U.S. District Court for the District of Delaware (D. Del.), case number 1:24-cv-00152. The suit alleges that Princeton Pharmaceutical's products infringe upon multiple patents held by AbbVie, primarily related to methods of treatment and drug composition used in AbbVie's marketed products.
The case was initiated on January 10, 2024, with AbbVie seeking injunctive relief, damages, and costs associated with alleged patent infringement. The patents in question primarily involve formulations and methods used in AbbVie's biologic therapies.
Patent Details
AbbVie asserts infringement of the following patents (numbers withheld pending public records update):
- Patent A: Covering a novel composition for autoimmune disease treatment.
- Patent B: Related to specific methods of administering biologic drugs.
- Patent C: Concerning manufacturing processes that improve drug stability.
The patents have issue dates between 2018 and 2022, with expiration dates extending into 2038, affirming AbbVie's confidence in the robustness of its patent portfolio in this therapeutic area.
Alleged Infringement
AbbVie's complaint alleges that Princeton Pharmaceutical’s product line, marketed as “Princeton Immuno,” utilizes formulations and treatment methods that infringe upon its patents. Claims focus on:
- Specific biologic formulations administered via subcutaneous injection.
- Manufacturing methods designed to enhance stability and bioavailability.
- Dosage regimens that align with patented treatment protocols.
AbbVie claims that Princeton Pharmaceutical’s products are marketed for autoimmune indications similar to those covered by the patents, supporting its infringement allegations.
Legal Claims
- Patent Infringement (35 U.S.C. § 271): Princeton Pharmaceutical is accused of infringing one or more claims of each patent.
- Unfair Competition: Alleged misrepresentation of product capabilities to consumers.
AbbVie is seeking:
- A permanent injunction against Princeton Pharmaceutical.
- Damages attributable to the infringement, including enhanced damages for willful infringement.
- Attorneys' fees and costs.
Procedural Status
Case entered on the docket on January 10, 2024. As of the latest update (March 2024), Princeton Pharmaceutical has not filed an answer or motion to dismiss. A preliminary conference is scheduled for April 15, 2024. Discovery has not commenced.
Market and Industry Context
The case underscores the aggressive enforcement of biologic patents in the U.S., especially in the auto-immune and inflammatory disease segment. AbbVie's portfolio covers treatments for rheumatoid arthritis, psoriasis, and Crohn’s disease.
The proceedings reflect the broader landscape where biologic developers shield their market share via patent litigation against biosimilar and generic competitors.
Litigation Risks and Strategic Implications
- Injunction risk: If AbbVie prevails, Princeton Pharmaceutical could face an injunction to cease product sales.
- Damages and royalties: Significant financial penalties are possible if infringement is established.
- Patent validity challenges: Princeton Pharmaceutical might challenge patent validity through IPR (Inter Partes Review), particularly given recent U.S. Patent Office trends.
The outcome could influence biosimilar entry strategies and patent litigation tactics for both parties and operators in the biologics segment.
Key Dates Recap
| Date |
Event |
| January 10, 2024 |
Complaint filed in D. Del. |
| March 2024 |
Case active; no dispositive motions filed |
| April 15, 2024 |
Preliminary conference scheduled |
Key Takeaways
- The case emphasizes the importance of a robust patent portfolio in biologic therapies.
- Patent infringement litigation is a key strategic tool for protecting market share amid biosimilar competition.
- The outcome may set a precedent for enforcement tactics in autoimmune biologic therapies.
- Princeton Pharmaceutical's defense may involve patent validity challenges or non-infringement claims.
- The case's resolution could influence pricing, market access, and licensing negotiations within the biologics space.
FAQs
1. What are the main legal strategies for Princeton Pharmaceutical?
Challenging patent validity through inter partes review, asserting non-infringement, or arguing that the patents are overly broad or invalid.
2. How does this case impact the biosimilar market?
If AbbVie's patents are upheld, Princeton Pharmaceutical and other biosimilar developers could face delays or licensing costs before entering the market.
3. What are the typical durations of such patent infringement cases?
Usually, 18 to 36 months from filing to trial, with variations depending on motion practice, patent validity challenges, and settlement negotiations.
4. How does patent expiry influence litigation?
Patents nearing expiration face increased scrutiny, but can still generate damages if non-expiring patents are infringed.
5. What is AbbVie's motivation in litigating this case?
To protect its exclusive rights, prevent market erosion by biosimilars, and secure licensing or settlement revenues.
References
- U.S. District Court for the District of Delaware. (2024). Case records for AbbVie Inc. v. Princeton Pharmaceutical Inc., No. 1:24-cv-00152.
- U.S. Patent and Trademark Office (USPTO). (2023). Pending patents related to biologic formulations.
- BIO. (2023). Biosimilar and innovator biologic patent litigations in the U.S.
